Afrigen Biologics and Vaccines is a Cape Town based biotechnology company strategically directed, supported and capitalised by Avacare Healthcare Group and the Industrial Development Corporation (IDC) of South Africa. It was founded in 2014 by Infectious Diseases Research Institute (IDRI) and Industrial Development Corporation (IDC) in Seattle. Afrigen drives a business strategy focussing on product development, bulk adjuvant manufacturing, and supply and distribution of key biologicals to address unmet healthcare needs. Through international partnerships and local capacity building, Afrigen has established the first ever adjuvant production and formulation technology centre on the African continent. This centre, in partnership with IDRI, a world leader in adjuvant development, focuses on next generation vaccine adjuvants, which are not only geared at preventing disease, but have therapeutic value. These adjuvants confer added potency and durability to vaccines.
In 2020 Agrifen was awarded the “mNRA Technology Transfer” title by World Health Organization (WHO) in partnership with Medicines Patent Pool (MPP) for the low and middle income countries.
Afrigen is dedicated to the local development and production of adjuvants for human and animal vaccines, as well as biologicals critical for Africa’s healthcare challenges.